Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06856213 |
Title | Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. (ERBIOTAX) |
Acronym | ERBIOTAX |
Recruitment | Recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | ESP |